mobile menu toggle

What we do here
changes lives everywhere.

Follow the science:

Identifying BCL-2 as a protein cancer cells use to prevent self-destruction leads to the BCL-2 inhibitor venetoclax, which has become a powerful agent in the fight against CLL and AML.

Identifying the EGFR mutation leads to the first broad application of precision medicine in lung cancer – which is paving the way for other active targeted lung cancer therapies.

Combining treatments of the PD-L1 and CTLA-4 pathways creates a “double assault” that is effective for melanoma, kidney and other cancers.

Understanding how cancer hijacks the body’s oxygen-sensing system leads to new therapies for kidney cancer, heart disease and more.

Dana-Farber shares patient stories which may include descriptions of actual medical results. Dana-Farber provides personalized care for each patient based on their unique needs; their experiences and results will vary.

One advanced cancer discovery after another for 75 years.

2nd Transatlantic Exchange Program focusses on Artificial Intelligence and Data Science in Oncology

Hundreds of attendees (on-site and virtually) joined the 2nd Transatlantic Exchange program on Friday, 5 May 2023, in Paris, France. The day-long session focused on artificial intelligence (AI) and data science in oncology. The Masterclass presented in collaboration with Dana-Farber Cancer Institute...

Learn more >

Next-Generation Drug Improves Progression-Free Survival in Relapsed Chronic Lymphocytic Leukemia

A head-to-head clinical trial in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) has found that zanubrutinib, a next-generation BTK inhibitor, was more effective at preventing disease progression and better tolerated than ibrutinib, the...

Learn more >

Dana-Farber research supports FDA approval of new therapy for certain patients with ovarian cancer

A novel antibody drug conjugate therapy whose clinical trial testing has been co-led by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) on November 14 for the treatment of recurrent platinum-resistant...

Learn more >

Symposium highlights 75 years of Dana-Farber science

Seventy-five years of research that has recast the understanding, treatment, and prevention of cancer took center stage at the Dana-Farber 2022 Scientific Symposium on Sept. 29. The all-day event featured nearly 20 presentations on topics such as the evolution of basic research at the Institute, the...

Learn more >

Three-drug combination slows progression of advanced kidney cancer

Patients treated with the three-drug combination had a 27% lower risk of progression or death compared to those on the two immunotherapy drugs. COSMIC-313 trial is the first phase 3 trial in metastatic renal cell carcinoma to use nivolumab plus ipilimumab, a contemporary standard of care, as the...

Learn more >

Dana-Farber Cancer Institute Celebrates 75th Anniversary

Commemoration to showcase decades of progress and leadership in cancer care and research Dana-Farber Cancer Institute is launching a year-long celebration of its 75th anniversary to highlight its history and progress in cancer care and transformative cancer research. In marking the notable...

Learn more >

  • Twitter logo
  • Pinterest logo
  • Facebook logo
  • LinkedIn logo
  • YouTube logo
  • Instagram logo
Best Children's Hospitals Award from US News
Best Hospitals Award from US News
Harvard Medical School
Magnet Recognized
Dana-Farber building